Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sec. Mattis listens to President Trump during a cabinet meeting. Photo by Saul Loeb/Getty Images.
U.S. Defense Secretary James Mattis is declining to comment on the alleged $700 million fraud at Theranos, much of which occurred while he sat on the blood-testing company's board of directors.
- Mattis joined the Theranos board after retiring from the military in 2013, and left after being nominated by President Trump.
- Statement from Mattis spokeswoman Dana White, who declined to elaborate: “Secretary Mattis was struck by the promise of technology and was looking for any technology solution to save lives on the battlefield. He resigned his position on the Theranos board on Dec. 16th prior to his confirmation.”